Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Thalasso is a marine biotechnology company focused on the sustainable harvesting and upcycling of invasive Sargassum seaweed. Utilizing autonomous harvesting technology and a proprietary biorefinery process, the company converts seaweed biomass into high-value products for the agriculture, cosmetic, and pharmaceutical industries. Their mission addresses the environmental crisis of Sargassum blooms in the Caribbean while creating a circular economy. The company operates primarily in Norway and Mexico, leveraging advanced robotics and chemical engineering to extract alginates and other bioactive compounds. By transforming a biological nuisance into a resource, Thalasso provides sustainable alternatives to synthetic chemicals and fertilizers. Their technology platform enables scalable, offshore collection of seaweed before it reaches the shore, preserving coastal ecosystems.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Thalasso Ocean.